Acta pharmaceutica Sinica. B
Cure8 research brief
Why This Matters
New oral micro- and nanomedicine strategies aim to deliver drugs more selectively to diseased areas in the gut, which could eventually improve treatments for IBD and colorectal cancer by increasing local effects and reducing systemic exposure.
Who Should Pay Attention
Researchers, translational scientists, and clinicians working on IBD or intestinal drug delivery; patients following research advances may find the topic of future therapies relevant.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This is a journal review article that summarizes advances in oral micro- and nanomedicines designed to overcome the intestine’s chemical, microbial, mechanical, and immunological barriers for diseases such as IBD and colorectal cancer.
The review outlines how micro- and nanoparticles can improve targeted drug accumulation and residence time in the gut, enabling more localized therapies. It describes different barrier types (chemical, microbial, mechanical, immune) and highlights recent strategies and challenges for designing oral micro/nanomedicines to reach pathological intestinal sites.
Because the source material is an abstract-level review, it provides a high-level synthesis of approaches and challenges rather than primary clinical trial results or specific treatment recommendations.
Keep In Mind
Abstract-level review: summarizes recent technological approaches and challenges but does not report primary clinical trial results.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationActa pharmaceutica Sinica. B
AuthorsYang M, Zhu Y, Li Q +7 more
Study typeReview, journal article
Indexed viaEurope PMC
Source typeResearch paper
PublishedJun 20, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Nanoparticle technologies in the diagnosis and therapy of gastrointestinal diseases: Progress, challenges, and future directions.
Nanoparticle technologies could eventually enable more targeted drug delivery and improved imaging for IBD and related GI diseases, which may lead to better diagnosis and less systemic side effects. However, translation...
Novel Clinical Intervention Pathway Based on the Pathogenesis Mechanism of Enterotoxigenic Bacteroides fragilis.
Research linking ETBF to intestinal inflammation and colorectal cancer suggests better detection and targeted therapies for this microbe could eventually affect IBD management and cancer risk assessment.
Oral hydrogel systems in lower gastrointestinal disorders: From disease-based therapy to microbiota-guided design.
IBD and other lower-GI disorders may benefit from oral hydrogel platforms that improve local drug delivery while deliberately engaging the gut microbiota. Understanding this research direction helps patients and...